In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Background Venous thromboembolism is a common complication of cancer, but the risk of
developing venous thromboembolism varies greatly among individuals and depends on …

Cancer patients are at increased risk of developing venous thromboembolism (VTE).
Guidelines recommend routine thromboprophylaxis in hospitalised acutely ill cancer …

Background The stratification of outpatients on chemotherapy for breast, colorectal, lung,
and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical …

Patients with cancer are heterogeneous concerning the risk for VTE. Some solid
malignancies including pancreatic, lung, colon-rectum, ovarian, and brain cancer are …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

The risk of venous thromboembolism (VTE) is increased in cancer patients. To improve
prediction of VTE in cancer patients, we performed a prospective and observational cohort …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Background. Retrospective studies have suggested an association between cancer-
associated venous thromboembolism (VTE) and patient survival. We evaluated a previously …